{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:57:31Z","timestamp":1792036651669,"version":"4.4.0"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K12110"],"award-info":[{"award-number":["JP18K12110"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor\u2019s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab\u2019s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg\/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg\/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.<\/jats:p>","DOI":"10.3390\/curroncol28010071","type":"journal-article","created":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T04:53:00Z","timestamp":1612068780000},"page":"726-739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-2333","authenticated-orcid":false,"given":"Masazumi","family":"Fujii","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Fukushima Medical University, Fukushima 960-1247, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kobayakawa","sequence":"additional","affiliation":[{"name":"Medical Research Center, Fukushima Medical University, Fukushima 960-1247, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-4306","authenticated-orcid":false,"given":"Kiyoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fukushima Medical University, Fukushima 960-1247, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-4731","authenticated-orcid":false,"given":"Akihiro","family":"Inano","sequence":"additional","affiliation":[{"name":"Medical Research Center, Fukushima Medical University, Fukushima 960-1247, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Nippon Medical School, Bunkyo-Ku, Tokyo 113-8602, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fujita Health University, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitake","family":"Mukasa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kumamoto University, Kumamoto 860-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-0107","authenticated-orcid":false,"given":"Takafumi","family":"Mitsuhara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 739-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka City University, Osaka 558-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-5888","authenticated-orcid":false,"given":"Shigeru","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University, Sapporo 060-0808, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kagawa University, Takamatsu 760-0016, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakatomi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Tokyo, Bunkyo-Ku, Tokyo 113-8654, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-5092","authenticated-orcid":false,"given":"Soichi","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Saitama Medical Center, Kawagoe 350-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Center for Liberal Arts and Sciences, Iwate Medical University, Morioka 020-0023, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4303-0600","authenticated-orcid":false,"given":"Taku","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fukushima Medical University, Fukushima 960-1247, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudathir","family":"Bakhit","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fukushima Medical University, Fukushima 960-1247, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BeatNF2 Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","article-title":"Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]","volume":"11","author":"Evans","year":"2009","journal-title":"Genet. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.wneu.2017.07.036","article-title":"Population Characteristics and Progressive Disability in Neurofibromatosis Type 2","volume":"106","author":"Iwatate","year":"2017","journal-title":"World Neurosurg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3171\/jns.2003.99.3.0480","article-title":"Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2","volume":"99","author":"Otsuka","year":"2003","journal-title":"J. Neurosurg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00006123-199704000-00007","article-title":"Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2","volume":"40","author":"Samii","year":"1997","journal-title":"Neurosurgery"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/MAO.0b013e3182355855","article-title":"Hearing preservation with the middle cranial fossa approach for neurofibromatosis type 2","volume":"32","author":"Friedman","year":"2011","journal-title":"Otol. Neurotol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3171\/ped.2007.106.4.255","article-title":"Hearing preservation surgery for neurofibromatosis Type 2\u2013related vestibular schwannoma in pediatric patients","volume":"106","author":"Slattery","year":"2007","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1227\/NEU.0000000000001125","article-title":"Internal auditory canal decompression for hearing maintenance in neurofibromatosis type 2 patients","volume":"79","author":"Bernardeschi","year":"2016","journal-title":"Neurosurgery"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/MAO.0b013e3182267eb7","article-title":"Middle fossa decompression for hearing preservation: A review of institutional results and indications","volume":"32","author":"Slattery","year":"2011","journal-title":"Otol. Neurotol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000156905","article-title":"Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: Indications and results","volume":"Volume 21","author":"Samii","year":"2008","journal-title":"Modern Management of Acoustic Neuroma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gugel, I., Grimm, F., Liebsch, M., Zipfel, J., Teuber, C., Kluwe, L., Mautner, V.-F., Tatagiba, M., and Schuhmann, M.U. (2019). Impact of Surgery on Long-Term Results of Hearing in Neurofibromatosis Type-2 Associated Vestibular Schwannomas. Cancers, 11.","DOI":"10.3390\/cancers11091376"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shinya, Y., Hasegawa, H., Shin, M., Sugiyama, T., Kawashima, M., Takahashi, W., Iwasaki, S., Kashio, A., Nakatomi, H., and Saito, N. (2019). Long-Term Outcomes of Stereotactic Radiosurgery for Vestibular Schwannoma Associated with Neurofibromatosis Type 2 in Comparison to Sporadic Schwannoma. Cancers, 11.","DOI":"10.3390\/cancers11101498"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1227\/NEU.0000000000000264","article-title":"Stereotactic Radiosurgery for Neurofibromatosis 2\u2014Associated Vestibular Schwannomas: Toward Dose Optimization for Tumor Control and Functional Outcomes","volume":"74","author":"Mallory","year":"2014","journal-title":"Neurosurgery"},{"key":"ref_13","first-page":"29","article-title":"Hearing preservation and tumour control after radiosurgery for NF2-related vestibular schwannomas","volume":"9","author":"Massager","year":"2013","journal-title":"B-ENT"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.24036","article-title":"Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: Tumor control and hearing preservation","volume":"115","author":"Phi","year":"2009","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3171\/2014.8.GKS141503","article-title":"Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2","volume":"121","author":"Sun","year":"2014","journal-title":"J. Neurosurg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3171\/2016.9.JNS161463","article-title":"Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: A matched cohort study with sporadic vestibular schwannomas","volume":"128","author":"Kruyt","year":"2017","journal-title":"J. Neurosurg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-010-0181-1","article-title":"Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2","volume":"98","author":"Sharma","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","article-title":"Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors","volume":"70","author":"Wong","year":"2010","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol. Neurotol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","article-title":"Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: Report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy","volume":"126","author":"Eminowicz","year":"2012","journal-title":"J. Laryngol. Otol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti\u2013vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2176\/nmc.oa.2019-0194","article-title":"Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients","volume":"60","author":"Fujii","year":"2019","journal-title":"Neurol. Med. Chir."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","article-title":"Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients","volume":"73","author":"Slusarz","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_31","first-page":"281","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neurooncol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","article-title":"Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort","volume":"131","author":"Morris","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/01.wnl.0000435746.02780.f6","article-title":"Hearing and facial function outcomes for neurofibromatosis 2 clinical trials","volume":"81","author":"Plotkin","year":"2013","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0033-1338262","article-title":"Antiangiogenic agents for nonmalignant brain tumors","volume":"74","author":"Hawasli","year":"2013","journal-title":"J. Neurol. Surg. Part B Skull Base"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.5301\/tj.5000313","article-title":"Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: Hearing improvement and tumor shrinkage","volume":"101","author":"Sponghini","year":"2015","journal-title":"Tumori J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.3892\/ol.2016.4347","article-title":"Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","article-title":"Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients","volume":"35","author":"Plotkin","year":"2014","journal-title":"Otol. Neurotol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/71\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:17:50Z","timestamp":1760159870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,31]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["curroncol28010071"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28010071","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,31]]}}}